

PUBLICATIONS AND PRESENTATIONS

TRANSFUSION SAFETY STUDY

Methodology

Published

1. Niland-Weiss J, Azen SP, Odom-Maryon T, Lui F, Hagerty C, Transfusion Safety Study Group. A microcomputer-based distributed data management system for a large cooperative study of transfusion associated acquired immunodeficiency syndrome. *Comput Biomed Res* 1987;20:225-243.
2. Fletcher MA, Baron GC, Ashman MR, Fischl MA, Klimas NG. Use of whole blood methods in assessment of immune parameters in immunodeficiency states. *Diagn Clin Immunol* 1987;5:69-81.
3. Edwards VM, Mosley JW, Transfusion Safety Study Group. Reproducibility in quality control of protein (Western) immunoblot assay for antibodies to human immunodeficiency virus. *Am J Clin Path* 1989;91:75-78.
4. Norman GL, Barker SS, Rasheed S, Transfusion Safety Study Group. Immunoblot reactivity of a non-HIV protein with human sera. *J Clin Lab Anal* 1989;3:148-151.
5. Fletcher MA, Azen SP, Adelsberg B, Gjerset GF, Hassett J, Kaplan J, Niland JC, Odom-Maryon T, Parker JW, Stites DP, Mosley JW, Transfusion Safety Study Group. Immunophenotyping in a multicenter study: the Transfusion Safety Study experience. *Clin Immunol Immunopathol* 1989;52:38-47.
6. Parker JW, Adelsberg B, Azen SP, Boone D, Fletcher MA, Gjerset GF, Hassett J, Kaplan J, Niland JC, Odom-Maryon T, Operskalski EA, Prince H, Scott D, Stites DP, Mosley JW, Transfusion Safety Study Group. Leukocyte immunophenotyping by flow cytometry in a multisite study: Standardization, quality control, and normal values in the Transfusion Safety Study. *Clin Immunol Immunopathol* 1990;55:187-220.
7. Buckley JD, Pike MC, Mosley JW, Transfusion Safety Study. Statistical approaches to evaluating prognostic indices in HIV infection. *AIDS* 1991;5:1398.
8. Busch MP, Henrard DR, Hewlett IK, Mehaffey WF, Epstein JS, Allain J-P, Lee T-H, Mosley JW, Transfusion Safety Study Group. Poor sensitivity, specificity, and reproducibility of detection of HIV-1 DNA in serum by polymerase chain reaction. *JAIDS* 1992;5:872-877.

9. Odom-Maryon T, Langholz B, Niland JC, Azen SP, Transfusion Safety Study Group. Generalization of normal discriminant analysis using Fourier series density estimators. *Statistics in Medicine* 1991;10:473-485.
10. Adams M, Lee T-H, Busch MP, Heitman J, Marshall GJ, Gjerset GF, Mosley JW, Transfusion Safety Study Group. Rapid freezing of whole blood or buffy coat samples for polymerase chain reaction and cell culture analysis: application to detection of human immunodeficiency virus in blood donor and recipient repositories. *Transfusion* 1993;33:504-8.

Published abstracts

1. Hassett J, Transfusion Safety Study. Flow cytometric evaluation of lymphocyte surface markers in the presence of nucleated red blood cells (NRBC). *Blood* 1989;-:162a.

Presentations

1. Norman GL, Weiss JN, Rasheed S, Transfusion Safety Study Group. Variations in antibody reactivity to HIV detected by protein immunoblot and correlation with individual clinical history (oral presentation). Fourth Conference on Modern Approaches to Vaccines: Modern Approaches to New Vaccines Including Prevention of AIDS, Cold Spring Harbor, New York, September 9-14, 1986.
2. Niland-Weiss J, Azen SP, Transfusion Safety Study Group. A microcomputer based distributed data management system for a large cooperative study of transfusion associated AIDS. Eighth Annual Meeting, Society for Clinical Trials, May 1987.
3. Mosley JW, Transfusion Safety Study Group. The Transfusion Safety Study (oral presentation). Third International Conference on AIDS, Washington, June 1987.
4. Transfusion Safety Study Group represented by JC Niland. Estimation of best absolute CD4 count from multiple pairings in two-color flow cytometry. Fifth International Conference on AIDS, Montreal, June 1989.
5. Transfusion Safety Study Group represented by MJ Nowicki. Evaluation of four commercially available anti-HTLV-I confirmatory assays. American Association of Blood Banks, Los Angeles, November 1990.

In Draft

1. Hassett J, Hilgartner M, Gjerset GF, Fletcher MA, Parker J, Donegan E, Mosley JW, Transfusion Safety Study Group. Lymphocyte phenotyping by flow cytometry in persons with nucleated red blood cells.
2. Nowicki M, Mosley JW, Transfusion Safety Study Group. Quality control in assays for antibody to hepatitis C virus.

HIV Studies of Donors and Recipients

Published

1. McClure E, Gaynor S, Veiga-Benach A, O'Neil D, Transfusion Safety Study Group. Counseling HIV infected recipients. *Nursing89* 1989 (January);10.
2. Kleinman SH, Niland JC, Azen SP, Operskalski EA, Barbosa LH, Chernoff AI, Edwards VM, Lenes BA, Marshall GJ, Nemo GJ, Norman GL, Perkins H, Pindyck J, Pitlick F, Rasheed S, Shriver K, Toy P, Tomasulo PA, Waldman A, Mosley JW, Transfusion Safety Study Group. Prevalence of antibodies to human immunodeficiency virus type-1 among blood donors prior to screening: The Transfusion Safety Study/NHLBI Donor Repository. *Transfusion* 1989;29:572-580.
3. Miller K, Donegan E, Curran P, Shelley TJ, Transfusion Safety Study Group. Effects of counselling on knowledge about HIV-1 among transfusion recipients and their partners. *AIDS Care* 1990;2:155-162.
4. Busch MP, Donegan E, Stuart M, Mosley JW, Transfusion Safety Study Group. Donor HIV-1 p24 antigenaemia and course of infection in recipients (Letter to the Editor). *Lancet* 1990;2:1342.
5. Busch MP, Taylor PE, Lenes BA, Kleinman SH, Stuart M, Stevens CE, Tomasulo PA, Allain J-P, Hollingsworth CG, Mosley JW, and the Transfusion Safety Study Group. Screening of selected male blood donors for p24 antigen of human immunodeficiency virus type 1. *New Engl J Med* 1990;323:1308-1312.
6. Donegan E, Lenes BA, Tomasulo PA, Mosley JW, Transfusion Safety Study Group. Transmission of HIV-1 by component type and duration of shelf storage before transfusion (Letter to the Editor). *Transfusion* 1990;30:851-852.
7. Donegan E, Stuart M, Niland JC, Sacks HS, Azen SP, Dietrich SL, Faucett C, Fletcher MA, Kleinman SH, Operskalski EA, Perkins HA, Pindyck J, Schiff ER, Stites DP, Tomasulo PA, Mosley JW, Transfusion Safety Study Group. Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations. *Ann Intern Med* 1990;113:733-739.
8. Buckley JD, Pike MC, Mosley JW, Transfusion Safety Study Group. Statistical approaches to evaluating prognostic indices in HIV infection (correspondence). *AIDS* 1991;5:1398.

9. Busch MP, Operskalski EA, Mosley JW, Stevens CE, Schiff ER, Kleinman SH, Lee H, Lee M, Harris M, Transfusion Safety Study Group. Epidemiologic background and long-term course of human immunodeficiency virus type 1-infected blood donors identified prior to routine laboratory screening. *Transfusion* 1994;34:858-864.
10. Diaz RS, Sabino EC, Mayer A, Mosley JW, Busch MP, Transfusion Safety Study Group. Dual human immunodeficiency virus type 1 infection and recombination in a dually-exposed transfusion recipient. *J Virol* 1995;69:3273-3281.
11. Operskalski EA, Stram DO, Lee H, Zhou Y, Donegan E, Busch MP, Stevens CE, Schiff ER, Dietrich SL, Mosley JW, Transfusion Safety Study Group. Human immunodeficiency virus type-1 infection: Relationship of risk group and age to rate of progression to AIDS. *J Infect Dis* 1995;172:648-55.
12. Busch MP, Operskalski EA, Mosley JW, Lee T-H, Henrard D, Herman S, Sachs DH, Harris M, Huang W, Stram DO, Transfusion Safety Study Group. Factors influencing HIV-1 transmission by blood transfusion. *J Infect Dis* 1996;174:26-33.
13. Operskalski EA, Busch MP, Mosley JW, Kedes DH. Blood donations and viruses (letter to the Editor). *Lancet* 1997;349:1327.
14. Operskalski EA, Busch MP, Mosley JW, Stram DO, Transfusion Safety Study Group. Comparative rates of disease progression among persons infected with the same or different HIV-1 strains. *J Acquir Immune Defic Syndr* 1997;15:145-150.
15. Operskalski EA, Mosley JW, Busch MP, Stram DO, Transfusion Safety Study Group. Influences of age, viral load, and CD4+ count on the rate of progression of HIV-1 infection to AIDS. *J Acquir Immune Defic Syndr Hum Retrovirol* 1997;15:243-44.
16. Operskalski EA, Stram DO, Busch MP, Huang W, Harris M, Dietrich SL, Schiff ER, Donegan E, Mosley JW, Transfusion Safety Study Group. Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. *Am J Epidemiol* 1997;146:655-61.

Published Abstracts

1. Donegan E, Transfusion Safety Study Group. Serum antibody positivity in recipients of anti-HIV positive blood. 39th Annual Meeting, American Association of Blood Banks, San Francisco. *Transfusion* 1986;26:576.

2. Gaynor S, McClure E, Transfusion Safety Study Group. Experience with notification of recipients of anti-human immunodeficiency virus positive transfusions. 39th Annual Meeting, American Association of Blood Banks, San Francisco. *Transfusion* 1986;26:594.
3. Donegan E, Perkins H, Vyas G, Transfusion Safety Study Group. Mortality in the recipients of blood in the Transfusion Safety Study. 28th Annual Meeting, American Society of Hematology. *Blood* 1986;86:296a.
4. Fletcher MA, Transfusion Safety Study Group. T4 and T8 lymphocyte counts in HIV positive and HIV negative blood donors. 28th Annual Meeting, American Society of Hematology. *Blood* 1986;86:125a.
5. Transfusion Safety Study Group represented by M Busch. HIV-1 p-24 antigen screening of male blood donors from high anti-HIV-1 prevalence areas. 42nd Annual Meeting, American Association of Blood Banks, New Orleans. *Transfusion* 1989;29:S203.
6. Transfusion Safety Study Group represented by M Busch. Clinical and immunological progression of HIV-1 infection in blood donors followed five years after seropositive donations (oral presentation). American Association of Blood Banks, Los Angeles. *Transfusion* 1990;--:---.
7. Transfusion Safety Study Group represented by MP Busch. Clinical and virological factors influencing transmission of HIV-1 by transfusion. American Association of Blood Banks, 45th Annual Meeting, San Francisco. *Transfusion* 1992;32(Suppl):56S.
8. Transfusion Safety Study Group represented by MJ Nowicki. Re-evaluation of anti-HIV seroprevalence among blood donors with contemporary screening assays. American Association of Blood Banks, 45th Annual Meeting, San Francisco. *Transfusion* 1992;32(Suppl):32S.
9. Transfusion Safety Study represented by EA Operskalski. Rate of progression among donors and recipients infected with the same or different HIV-1 strains. 49th Annual Meeting of the American Association of Blood Orlando. *Transfusion* 1996;36(Suppl):32S.

Presentations

1. Mosley JW, Transfusion Safety Study Group. Screening of donors for antibodies to human immunodeficiency virus: Public health impact and adequacy of present methods (oral presentation). NIH Consensus Development Conference on the

- Impact of HTLV-III Antibody Testing on Public Health, July 1986.
2. Kleinman S, Transfusion Safety Study Group. The infectivity of anti-HIV-positive blood components. Third International Conference on AIDS, Washington, June 1987.
 3. Niland JC, Transfusion Safety Study Group. Association of donor characteristics with transmission of HIV infection to recipients. Third International Conference on AIDS, Washington, June 1987.
 4. Operskalski EA, Transfusion Safety Study Group. HIV high-risk indices among anti-HIV-negative blood donors. Third International Conference on AIDS, Washington, June 1987.
 5. The Transfusion Safety Study Group represented by E Donegan. Course of HIV infection in transfusion recipients. Fourth International Conference on AIDS, Stockholm, June 1988.
 6. Transfusion Safety Study Group represented by JW Mosley. HIV-1 p24 antigen screening of male blood donors in localities with high anti-HIV-1 prevalence. Presentation to the Food and Drug Administration's Advisory Committee on Blood and Blood Products. Bethesda, MD, March 23, 1989.
 7. Transfusion Safety Study Group represented by E Donegan. Risk of heterosexual transmission of HIV-1 from recipients of blood and blood products. Fifth International Conference on AIDS, Montreal, June 1989.
 8. Transfusion Safety Study Group represented by M Stuart. AIDS among HIV-1 infected recipients in relation to its occurrence in their specific donors. Fifth International Conference on AIDS, Montreal, June 1989.
 9. Transfusion Safety Study Group represented by EA Operskalski. Transfusion-transmitted HIV infection: rate of progression to AIDS (oral presentation). Seventh International Conference on AIDS, Florence, June 1991.
 10. Transfusion Safety Study Group represented by JW Mosley. Course of HIV-1 infection among persons infected with the same strain. Seventh International Conference on AIDS, Florence, June 1991.
 11. Transfusion Safety Study Group represented by MP Busch. Transmission of HIV-1 by transfusion. IXth International Conference on AIDS, Berlin, June 1993.
 12. Diaz R, Sabino E, Mayer A, Mosley JW, Busch MP. Analysis of HIV quasi-species in a recipient of two seropositive platelet transfusions. First National Conference on Human Retroviruses, Washington DC, 1993.

13. Transfusion Safety Study Group represented by EA Operskalski. Application of HIV RNA quantitation to research in transfusion medicine. 48th Annual Meeting of the American Association of Blood Banks. New Orleans, November 11-15, 1995.
14. Transfusion Safety Study Group represented by EA Operskalski. Role of viral load in transfusion- and heterosexual-transmission of HIV-1 infection. 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 1996.

HTLV Studies of Donors and Recipients

Published

1. Operskalski EA, Schiff ER, Kleinman SH, Busch MP, Taylor PE, Parks WP, Lee HH, Tomasulo PA, Donegan E, Stuart M, Hollingsworth CG, Nemo GJ, Mosley JW, and the Transfusion Safety Study Group. Epidemiologic background of blood donors with antibody to human T-cell lymphotropic virus (Rapid Communication). *Transfusion* 1989;29:746-748.
2. Donegan E, Busch MP, Galleshaw JA, Shaw GM, Mosley JW, Transfusion Safety Study Group. Transfusion of blood components from a donor with human T-lymphotropic virus type II (HTLV-II) infection (Case Report). *Ann Intern Med* 1990;113:555-556.
3. Parks WP, Lenes BA, Tomasulo PA, Schiff ER, Parks ES, Shaw GM, Lee HH, Yan H-Q, Lai S, Hollingsworth CG, Nemo GJ, Mosley JW, and the Transfusion Safety Study Group. Human T-cell lymphotropic virus infection among blood donors in South Florida. *JAIDS* 1991;4:89-96.
4. Fletcher MA, Gjerset GF, Hassett J, Donegan E, Parker JW, Mosley JW, Transfusion Safety Study Group. Lymphocyte immunophenotypes among anti-HTLV-I/II-positive blood donors and recipients. *JAIDS* 1991;4:628-632.
5. Donegan E, Pell P, Lee H, Shaw GM, Mosley JW, Transfusion Safety Study Group. Transmission of human T-lymphotropic virus type I by blood components from a donor lacking anti-p24: a case report. *Transfusion* 1992;32:68-91.
6. Donegan E, Lee H, Operskalski EA, Shaw G, Kleinman S, Busch MP, Stevens CE, Schiff ER, Nowicki MJ, Hollingsworth CG, Mosley JW, Transfusion Safety Study Group. Transfusion transmission of retroviruses: human T lymphotropic virus types I and II compared with human immunodeficiency virus type 1. *Transfusion* 1994;34:478-483.

Published Abstracts

1. Transfusion Safety Study Group represented by E Donegan. Comparison of HTLV-I/II with HIV-1 transmission by component type and shelf storage before administration. 42nd Annual Meeting, American Association of Blood Banks, New Orleans. *Transfusion* 1989;29:S130.

2. Transfusion Safety Study Group represented by PA Tomasulo. Human T-cell lymphotropic virus infection among blood donors: epidemiologic pattern compared with that of human immunodeficiency virus type 1. 42nd Annual Meeting, American Association of Blood Banks, New Orleans. Transfusion 1989;29:S133.
3. Transfusion Safety Study Group represented by MA Fletcher. Effect of HTLV I/II seropositivity on lymphocyte phenotypes in blood donors. 31st annual meeting, American Society of Hematology, Atlanta. Blood 1989;74:246a.
4. Transfusion Safety Study Group represented by JW Mosley. HTLV-I/II infection of blood recipients and its early effect on lymphocyte subpopulations. 31st annual meeting, American Society of Hematology, Atlanta. Blood 1989;74:178a.
5. Transfusion Safety Study Group represented by S Kleinman. Evaluation of donors with an HTLV-I antibody indeterminate results (oral presentation). American Association of Blood Banks, Los Angeles. Transfusion 1990;--(Suppl):--S.
6. Transfusion Safety Study represented by P Taylor. Epidemiologic characteristics of anti-HTLV positive blood donors. American Association of Blood Banks, Los Angeles. Transfusion 1990;--(Suppl):--S.
7. Transfusion Safety Study Group represented by E Donegan. Transfusion-transmitted HTLV-I and II: infectivity and clinical consequences in donors and recipients (oral presentation). American Association of Blood Banks, Baltimore. Transfusion 1991;31(Suppl):41S.

Presentations

1. The Transfusion Safety Study Group represented by WP Parks. HTLV-I seropositive blood donors in South Florida. Fourth International Conference on AIDS, Stockholm, June 1988.
2. Mosley JW. Antibodies to HTLV-I/II among blood donors in four cities of the United States. Presentation to the Advisory Committee on Blood and Blood Products, Food and Drug Administration. Rockville, MD, November 18, 1988.
3. Transfusion Safety Study Group represented by JW Mosley. Observations concerning HTLV-I/II in the Transfusion Safety Study. Current Issues in Human Retrovirology: HTLV, Port of Spain, Trinidad, April 1, 1989.
4. Transfusion Safety Study Group represented by MA Fletcher. Immunophenotypes of anti-HTLV-I positive (+) blood donors. Fifth International Conference on AIDS, Montreal, June 1989.

5. Transfusion Safety Study Group represented by JW Mosley. Antibody to HTLV I/II among blood donors in four cities of the United States. Fifth International Conference on AIDS, Montreal, June 1989.
6. Transfusion Safety Study Group represented by E Donegan. Five-year follow-up of blood donors serologically indeterminate for HTLV-I/II. Third Annual Retrovirology Conference, Hawaii, February 1990.
7. Transfusion Safety Study Group represented by MA Fletcher. Lymphocyte phenotypes in HTLV seropositive blood donors and recipients. Third Annual Retrovirology Conference, Hawaii, February 1990.
8. Transfusion Safety Study Group represented by JW Mosley. HTLV transmission by blood transfusion (oral presentation). Third Annual Retrovirology Conference, Hawaii, February 1990.
9. Transfusion Safety Study Group represented by EA Operskalski. Serologic status of household contacts of anti-HTLV(+) donors. Third Annual Retrovirology Conference, Hawaii, February 1990.
10. Transfusion Safety Study Group represented by EA Operskalski. Serologic status of household contacts of anti-HTLV(+) donors. XII Scientific Meeting, International Epidemiologic Association, Los Angeles, August 1990.
11. Transfusion Safety Study Group represented by E Donegan. HTLV transmission by blood transfusion in the United States (oral presentation). Fourth Annual Retrovirology Conference, Jamaica, February 1991.
12. Transfusion Safety Study Group represented by MA Fletcher. Lymphocyte immunophenotypes of HTLV-I and HTLV-II blood donors. Fourth Annual Retrovirology Conference, Jamaica, February 1991.
13. Transfusion Safety Study Group represented by E Donegan. Transfusion transmission of retroviruses. IXth International Conference on AIDS, Berlin, June 1993.
14. Transfusion Safety Study Group represented by MJ Nowicki. T-lymphocytes subpopulations are more affected by HTLV-I than HTLV-II infection. Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 1996.

Congenital Clotting Disorders

Published

1. Kaplan J, Sarnaik S, Lusher JM, Transfusion Safety Study Group. Increase Leu2+ Leu7+ lymphocytes in HIV-1 seropositive patients with hemophilia repeatedly treated with clotting factor concentrates. *Clin Immunol Immunopath* 1988;46:337-341.
2. Dietrich SL, Mosley JW, Lusher JM, Hilgartner MW, Operskalski EA, Habel L, Aledort LM, Gjerset GF, Koerper MA, Lewis BH, Pegelow CH, Transfusion Safety Study Group. Transmission of human immunodeficiency virus type 1 by dry-heated clotting factor concentrates. *Vox Sang* 1990;59:129-135.
3. Lusher JM, Operskalski EA, Aledort LM, Dietrich SL, Gjerset GF, Hilgartner MW, Koerper MA, Pegelow CH, Lee H, Mosley JW, Transfusion Safety Study. Risk of human immunodeficiency virus type 1 infection among sexual and nonsexual household contacts of persons with congenital clotting disorders. *Pediatrics* 1991;88:242-249.
4. Aledort LM, Hilgartner MW, Pike MC, Gjerset GF, Koerper MA, Lian ECY, Lusher JM, Mosley JW, Transfusion Safety Study Group. Variability in serial CD4 counts and relation to progression of HIV-1 infection to AIDS in haemophiliac patients. *Br Med J* 1992;304:212-216.
5. Fletcher MA, Mosley JW, Hassett J, Gjerset GF, Kaplan J, Parker JW, Donegan E, Lusher JM, Lee H, Transfusion Safety Study Group. Effect of age on HIV-1 induced changes in lymphocyte populations among persons with congenital clotting disorders. *Blood* 1992;80(3):831-840.
6. Nowicki MJ, Mosley JW, Koerper MA, Aledort LM, Lusher JM, Hilgartner MW. Passive antibody to hepatitis A virus in US haemophiliacs. (Letter to the Editor) *Lancet* 1993;341:562.
7. Hilgartner MW, Buckley JD, Operskalski EA, Pike MC, Mosley JW, Transfusion Safety Study Group. Purity of factor VIII concentrates and serial CD4⁺ counts. The Transfusion Safety Study Group. *Lancet* 1993;341:1373-4.
8. Hassett J, Gjerset GF, Mosley JW, Fletcher MA, Donegan E, Parker JW, Counts RB, Aledort LM, Lee H, Pike MC, Transfusion Safety Study Group. Effect on lymphocyte subsets of clotting factor therapy in human immunodeficiency virus-1-negative congenital clotting disorders. *Blood* 1993;82:1351-7.

9. Mosley JW, Nowicki MJ, Kasper CK, Donegan E, Aledort LM, Hilgartner MW, Operskalski EA, Transfusion Safety Study Group. Hepatitis A virus transmission by blood products in the United States. *Vox Sanguinis* 1994;67(suppl 1):24-28.
10. Gjerset GF, Pike MC, Mosley JW, Hassett J, Fletcher MA, Donegan E, Parker JW, Counts RB, Zhou Y, Kasper KC, Operskalski EA, Transfusion Safety Study Group. Effect of low- and intermediate-purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders. *Blood* 1994;84:1666-71.
11. Operskalski EA, Mosley JW, for the Transfusion Safety Study Group. Pooled plasma derivatives and Creutzfeldt-Jakob disease (Letter to the Editor). *Lancet* 1995;346:1224.

Submitted

1. Kasper CK, Koerper M, Lusher JM, Donegan E, Nowicki M, Mosley JW, Transfusion Safety Study Group. Hepatitis C virus infection from factor IX concentrates in contemporary use. To be resubmitted.
2. Stram DO, Buckley JD, Pike MC, Gjerset GF, Aledort LM, Mosley JW, Transfusion Safety Study Group. Short- and intermediate-term individual variability in CD4 trends among HIV-1 infected patients. To be resubmitted.

Published Abstracts

1. Aledort LM, Transfusion Safety Study Group. HIV status and T-cell subsets in congenital coagulation disorders. 28th Annual Meeting, American Society of Hematology. *Blood* 1986;86:120a.
2. Operskalski E, Transfusion Safety Study Group. Transmission of human immunodeficiency virus infection to household contacts of persons with congenital hematologic disorders. 28th Annual Meeting, American Society of Hematology. *Blood* 1986;86:131a.
3. Transfusion Safety Study Group represented by JW Mosley. Effect of age on the expression of human immunodeficiency virus infection among hemophiliacs. 29th Annual Meeting, American Society of Hematology. *Blood* 1987;70:125a.
4. Transfusion Safety Study group represented by CH Pegelow. Effect of human immunodeficiency virus infection upon hepatitis B virus antibodies in persons with congenital clotting disorders. 29th Annual Meeting, American Society of Hematology. *Blood* 1987;70:125a.

5. Lusher JM, Aledort LM, Sarnaik S, Mosley J, Transfusion Safety Study Group. HIV status, T cell subsets, blood product use, and hematologic abnormalities in congenital coagulation disorders (CCD). Eleventh International Congress on Thrombosis and Haemostasis, Brussels, July 1987. *Thromb Haemost* 1987;58:510.
6. Lusher JM, Aledort LM, Hilgartner M, Mosley JW, Operskalski EA, Transfusion Safety Study Group. Transmission of human immunodeficiency virus infection to household contacts of persons with congenital hematologic disorders. Eleventh International Congress on Thrombosis and Haemostasis, Brussels, July 1987. *Thromb Haemost* 1987;58:510.
7. Transfusion Safety Study Group represented by GF Gjerset. Impact of allotypic proteins in the treatment of HIV-1 infected hemophiliacs. 31st Annual Meeting, American Society of Hematology, Atlanta. *Blood* 1989;74:296a.
8. Transfusion Safety Study Group represented by LM Aledort. Chronically transfused (TX) patients (PTS) not infected with HIV-1 by antibody and polymerase chain reaction (PCR). 32nd Annual Meeting, American Society of Hematology, Boston. *Blood* 1990;76:394a.
9. Transfusion Safety Study Group represented by GF Gjerset. Transfusion of cellular components does not affect CD4 counts in anti-HIV+ hemophiliacs. 32nd Annual Meeting, American Society of Hematology, Boston. *Blood* 1990;76:399a.
10. Transfusion Safety Study Group represented by LM Aledort. Relationship of CD4 level to progression of HIV-1 infection. Thirteenth Congress of the International Society of Thrombosis and Haemostasis, Amsterdam, July 1991.
11. Transfusion Safety Study Group represented by JM Lusher. Anti-HCV prevalence in relation to type and amount of clotting factor therapy in congenital clotting disorders. Thirteenth Congress of the International Society of Thrombosis and Haemostasis, Amsterdam, July 1991.
12. Transfusion Safety Study Group represented by MW Hilgartner. Comparison of effect on CD4 counts of treatment with high and intermediate purity clotting factor concentrates. Thirteenth Congress of the International Society of Thrombosis and Haemostasis, Amsterdam, July 1991.
13. Transfusion Safety Study Group represented by MJ Nowicki. Absence of detectable anti-HCV_{c100} in the presence of other HCV specific antibodies. American Association of Blood Banks, Baltimore, MD. *Transfusion* 1991;31(Suppl):12s.

14. Transfusion Safety Study Group represented by JM Lusher. Hepatitis C virus (HCV) transmission by clotting factor concentrates (CF Con) in current use. International Society of Hematology and the American Society of Hematology. Blood 1991;78(Suppl):355a.
15. Transfusion Safety Study Group represented by MW Hilgartner. Effect of intermediate and high purity factor VIII concentrates on CD4+ counts in HIV-infected persons. International Society of Hematology and the American Society of Hematology, Anaheim, CA. Blood 1992;80(Suppl):223a.
16. Transfusion Safety Study Group represented by MJ Nowicki. Lack of evidence for hepatitis A virus transmitted by clotting factor concentrates in US. XIVth Congress of the International Society of Thrombosis and Haemostasis, New York, July 1993.
17. Transfusion Safety Study represented by JW Mosley. HAV infection among hemophilic subjects and their household contacts. 35th Annual Meeting of American Society of Hematology, St. Louis. Blood 1993;82(Suppl):154a.
18. Transfusion Safety Study Group represented by JW Mosley. Evaluating apparent HAV seroconversion associated with clotting factor concentrates. XXIII Congress of the International Society of Blood Transfusion. Amsterdam. Vox Sang 1994;67:39.
19. Transfusion Safety Study Group represented by GF Gjerset. splenectomy and HIV-1 progression. Blood 1994;--(Suppl):---.
20. Transfusion Safety Study Group represented by MJ Nowicki. Infrequency of parvovirus viremia in HIV-infected hemophiliacs with abrupt red cell decreases. Transfusion 1995;35(Suppl):64S.

Presentations

1. Fletcher MA, Transfusion Safety Study Group. The relationship of antibody to HIV, age, sex and treatment to lymphocyte subsets in congenital clotting disorder patients. Third International Conference on AIDS, Washington, June 1987.
2. Gjerset GF, Transfusion Safety Study Group. Laboratory and clinical manifestations of HIV infection in patients with congenital clotting disorders (CCD). Third International Conference on AIDS, Washington, June 1987.

3. Transfusion Safety Study Group represented by SL Dietrich. Anti-HIV seroconversion among congenital clotting disorder patients receiving heat-treated clotting factor concentrates (oral presentation). Review of Data on Therapeutic Products Used in Treating Hemophilia, Centers for Disease Control, Atlanta, January 1988.
4. Transfusion Safety Study Group represented by JW Mosley. Monitoring for transmission of hepatitis viruses by heat-treated clotting factor concentrates. Review of Data on Therapeutic Products Used in Treating Hemophilia, Centers for Disease Control, Atlanta, January 1988.
5. The Transfusion Safety Study Group represented by JW Mosley. HIV transmission by anti-HIV donor-screened, heat-treated clotting factor concentrates (oral presentation). Fourth International Conference on AIDS, Stockholm, June 1988.
6. The Transfusion Safety Study Group represented by LM Aledort. HIV and HBV markers in congenital coagulation defect CCD patients. Fourth International Conference on AIDS, Stockholm, June 1988.
7. The Transfusion Safety Study Group represented by GF Gjerset. ALT levels and anti-HIV status among treated patients with congenital clotting disorders (CCD). Fourth International Conference on AIDS, Stockholm, June 1988.
8. Transfusion Safety Study Group represented by GF Gjerset. Effect of clotting factor treatment on CD4 counts in anti-HIV-1 (+) hemophiliacs. Fifth International Conference on AIDS, Montreal, June 1989.
9. Transfusion Safety Study Group represented by JW Mosley. Hepatitis D virus (HDV) infection among persons with treated congenital clotting disorders (CCD). 1990 International Symposium on Viral Hepatitis and Liver Disease, Houston, April 1989.
10. Transfusion Safety Study Group represented by MW Hilgartner. Fall of CD4 lymphocytes in HIV-1 infected patients with coagulation diseases. Sixth International Conference on AIDS, San Francisco, June 1990.
11. Transfusion Safety Study Group represented by JW Mosley. Age-specific differences in lymphocyte subpopulations associated with HIV-1 infection. Sixth International Conference on AIDS, San Francisco, June 1990.
12. Transfusion Safety Study Group represented by GF Gjerset. Lack of association in anti-HIV(+) hemophiliacs between decline in CD4 and treatment with clotting factor concentrates. Sixth International Conference on AIDS, San Francisco, June 1990.

13. Transfusion Safety Study Group represented by JW Mosley. Anti-HCV seroconversion among persons treated with blood components and concentrates for congenital clotting disorders. Second International Symposium on HCV, Los Angeles, November 1990.
14. Transfusion Safety Study Group represented by EA Operskalski. Comparison of HCV with HBV infection among sexual and non-sexual household contacts of persons with congenital clotting disorders. Second International Symposium on HCV, Los Angeles, November 1990.
15. Transfusion Safety Study Group represented by MJ Nowicki. Anti-HCV pattern in resolved and chronic HCV infection. Second International Symposium on HCV, Los Angeles, November 1990.
16. Transfusion Safety Study Group represented by MA Fletcher. Age and HIV-1 effects on lymphocyte phenotypes in congenital clotting disorder patients. Clinical Immunology Society, November 1990.
17. Transfusion Safety Study Group represented by LM Aledort. Serial CD4 counts in relation to the decision to treat asymptomatic HIV-1 infection (oral presentation). Seventh International Conference on AIDS, Florence, June 1991.
18. Transfusion Safety Study Group represented by JW Mosley. Possible HCV re-infection of hemophiliacs with antecedent anti-c22-3 and anti-c33c but no anti-c100-3. International Symposium on Viral Hepatitis, Madrid, Spain, January-February 1992.
19. Transfusion Safety Study Group represented by MJ Nowicki. Selective decline of anti-HCV_{c100-3} antibodies in the HCV-infected individuals with hemophilia. International Symposium on Viral Hepatitis, Madrid, Spain, January-February 1992.
20. Transfusion Safety Study Group represented by JW Mosley. Quantitative changes in HIV-1 p24 antigen in relation to clinical AZT therapy. Eighth International Conference on AIDS, Amsterdam, July 1992.
21. Transfusion Safety Study Group represented by GF Gjerset. The role of CD8 subsets in subsequent development of AIDS. Eighth International Conference on AIDS, Amsterdam, July 1992.
22. Transfusion Safety Study Group represented by MW Hilgartner. Effect of intermediate and high purity factor VIII concentrates on CD4+ counts in HIV-infected persons.

- International Society of Hematology and the American Society of Hematology, Anaheim, CA, November, 1992.
23. Transfusion Safety Study represented by J Hassett. Effect of clotting factor therapy on peripheral blood lymphocyte activation markers. 12th International Convocation on Immunology, Buffalo, May 1994.
 24. Transfusion Safety Study represented by EA Operskalski. Effect of allogenic proteins in clotting factor concentrates on peripheral blood lymphocytes. 12th International Convocation on Immunology, Buffalo, May 1994.
 25. Transfusion Safety Study represented by JW Mosley. Surveillance of virus transmission by pooled plasma derivatives. 12th International Convocation on Immunology, Buffalo, May 1994.
 26. Transfusion Safety Study represented by EA Operskalski. Occurrence of hepatitis C virus infection, and interaction with HIV, among persons with hemophilia. Symposium on Liver Disease in Hemophilia: New Directions in Diagnosis, Management, and Treatment, sponsored by the National Hemophilia Foundation and George Washington University Medical Center. Atlanta, March 1995.
 27. Transfusion Safety Study represented by EA Operskalski. Sexual and nonsexual household transmission of hepatitis B and hepatitis C virus infections. Symposium on Liver Disease in Hemophilia: New Directions in Diagnosis, Management, and Treatment, sponsored by the National Hemophilia Foundation and George Washington University Medical Center. Atlanta, March 1995.
 28. Transfusion Safety Study represented by MJ Nowicki. Low hemoglobin levels in HIV(+) hemophiliacs appear not to be associated with B19 parvoviremia. Symposium on Parvoviruses, sponsored by the European Plasma Fractionation Association and the Scottish National Blood Transfusion Services, Edinburgh, March 1995.
 29. Transfusion Safety Study Group represented by EA Operskalski. HCV mortality among HIV-uninfected hemophiliacs. Biennial Scientific Meeting of the International Association for the Study of the Liver, Capetown, South Africa, February 1996.
 30. Transfusion Safety Study Group represented by JW Mosley. Effect of HDV co-infection on HBV transmission to sexual and non-sexual household contacts. Biennial Scientific Meeting of the International Association for the Study of the Liver, Capetown, South Africa, February 1996.
 31. Transfusion Safety Study Group represented by SL Dietrich. Significance of non-AIDS deaths among HIV-1 infected

hemophiliacs. XXII International Congress of the World
Federation of Hemophilia, Dublin, Ireland, June 1996.

In Draft

1. Gjerset GF, Mosley JW, Pegelow CH, Lusher JM, Dietrich SL, Donegan E, Aledort LM, Operskalski EA, Transfusion Safety Study Group. Epidemiologic determinants of human immunodeficiency virus type 1 prevalence among persons with congenital clotting disorders.
2. Operskalski EA, et al. Sexual and nonsexual household transmission of hepatitis B and hepatitis C viruses.
3. Operskalski EA et al. Occurrence of hepatitis C virus infection, and interaction with HIV, among persons with hemophilia.
4. Lusher JM, Hilgartner MW, Mosley JW, Govindarajan S, Gjerset GF, Kasper CK, Koerper MA, Lian EYC, Transfusion Safety Study Group. Hepatitis D virus infection of persons with congenital clotting disorders.
5. Pegelow C, Aledort LM, Nowicki MJ, Mosley JW, et al. Human immunodeficiency virus type-1 and hepatitis B virus infection in patients with congenital clotting disorders.
6. Nowicki MJ, Mosley JW, et al. HAV infection among hemophilic subjects and their household contacts.
7. Pegelow C, Aledort LM, Nowicki MJ, Mosley JW et al. Hepatitis B seroconversions in patients with congenital clotting disorders.

Congenital Anemias

Published papers

1. Wong W-Y, Powars DR, Operskalski EA, Hassett J, Parker JW, Sarnaik SA, Pegelow CH, Hilgartner MW, Johnson CS, Zhou Y, Ku P-Y, Mosley JW, Transfusion Safety Study Group. Blood transfusions and immunophenotypic alterations of lymphocyte subsets in sickle cell anemia. *Blood* 1995;35:2091-7.
2. Wong W-Y, Zhou Y, Operskalski EA, Hassett J, Powars DR, Mosley JW, Transfusion Safety Study Group. Hematologic profile and lymphocyte subpopulations in hemoglobin SC disease: Comparison with hemoglobin SS and Black controls. *Am J Hematol* 1996;52:150-4.

Published abstracts

1. Pegelow CH, Calmann ME, O'Brien TA, Transfusion Safety Study Group. Hepatitis C antibody (anti-HCV) prevalence in transfused congenital anemia (CA) patients. *Blood* 1991;78(Suppl):354a.
2. Wong WY. Immunophenotypic alterations of lymphocyte subsets in sickle cell anemia (SCA) *Blood* 1993;82(Suppl):585a.

Abstracts submitted

1. Nowicki MJ, Mosley JW, Michel F. Frequency of parvovirus B19 (HPV) infections among congenital anemia (CA) patients and their household contacts. 49th Annual Meeting of the American Association of Blood Banks, Orlando, FL, October 1996.

Other (Including multi-group studies)

Published

1. Gjerset G, Vyas GN, Bhat R, Operskalski EA, Transfusion Safety Study Group. Phenotypes for group-specific component among patients exposed to human immunodeficiency virus by transfusions. *J Infect Dis* 1988;157:609-10.
2. Govindarajan S, Edwards VM, Stuart ML, Operskalski EA, Mosley JW, Transfusion Safety Study Group. Influence of human immunodeficiency virus infection on expression of chronic hepatitis B and D virus infections. In: Zuckerman AJ (ed), *Viral Hepatitis and Liver Disease*, Alan R Liss, Inc, New York, 1987, pp 201-4.
3. Brown NA, Kovacs A, Lui C-R, Hur C, Zaia JA, Mosley JW, Transfusion Safety Study Group. Prevalence of antibody to human herpesvirus 6 among blood donors infected with HIV (Letter to the Editor). *Lancet* 1988; Nov 12;2(8620):1146.
4. Mosley JW, Nowicki M, Kleinman SH, Dietrich SL, Transfusion Safety Study Group. Reactivation of hepatitis B (Letter to the Editor). *Lancet* 1989;1:1083-4.
5. Lang DJ, Kovacs AAS, Zaia JA, Doelkin G, Niland JC, Aledort L, Azen SP, Fletcher MA, Gauderman J, Gjerset GJ, Lusher J, Operskalski EA, Parker JW, Pegelow C, Vyas GN, Mosley JW, Transfusion Safety Study Group. Seroepidemiologic studies of cytomegalovirus and Epstein-Barr virus infections in relation to human immunodeficiency virus type 1 infection in selected recipient populations. *JAIDS* 1989;2:540-549.
6. Aledort LM, Operskalski EA, Dietrich SL, Koerper MA, Gjerset GF, Lusher JM, Lian ECY, Mosley JW, Transfusion Safety Study Group. Low CD4+ counts in a study of transfusion safety. (Letter) *New Engl J Med* 1993;328:441-442.

Published Abstracts

1. Mosley JW, Govindarajan S, Edwards VM, and the Transfusion Safety Study Group. Expression of chronic hepatitis B and D virus infections in persons with human immunodeficiency virus infection. *Hepatology* 1986;--:--.
2. Transfusion Safety Study Group represented by M Hilgartner. Human T-cell lymphotropic virus (HTLV) types I/II infection among persons treated with blood components. 31st annual meeting, American Society of Hematology, Atlanta. *Blood* 1989;74:101a.

3. Transfusion Safety Study Group represented by MJ Nowicki. Potential for HEV transmission by blood. XXIII Congress of the International Society of Blood Transfusion. Amsterdam. Vox Sang 1994;67:39.
4. Transfusion Safety Study Group represented by MJ Nowicki. "Transient" anti-HIV-1 seropositivity. XXIII Congress of the International Society of Blood Transfusion. Amsterdam. Vox Sang 1994;67:108.
5. Operskalski EA, Kedes DH, Ganem D, Busch MP. A study of the potential transmissibility by transfusion of Kaposi's sarcoma-associated herpesvirus (KSHV)/human herpesvirus 8 (HHV8). 49th Annual Meeting of the American Association of Blood Banks. Orlando. Transfusion 1996;36(Suppl):57S.

Presentations

1. Govindarajan S and the Transfusion Safety Study Group. Influence of human immunodeficiency virus infection upon expression of chronic hepatitis B and D virus infection. 1987 International Symposium on Viral Hepatitis and Liver Disease. London, May 26-28, 1987.
2. The Transfusion Safety Study Group represented by E Schiff. HBsAg status and expression of HIV infection as AIDS. Fourth International Conference on AIDS, Stockholm, June 1988.
3. The Transfusion Safety Study Group represented by DJ Lang. HIV and herpesviruses: Serologic and immunologic relationships. Fourth International Conference on AIDS, Stockholm, June 1988.
4. The Transfusion Safety Study Group represented by EA Operskalski. Transient anti-HIV seropositivity. Fourth International Conference on AIDS, Stockholm, June 1988.
5. Transfusion Safety Study Group represented by EA Operskalski. Early HIV-1 influence on non-AIDS defined malignancies. Fifth International Conference on AIDS, Montreal, June 1989.
6. Transfusion Safety Study Group represented by MA Fletcher. Co-infection with HIV-1 and HTLV: effect on lymphocyte phenotype. Seventh International Conference on AIDS, Florence, June 1991.
7. Transfusion Safety Study Group represented by EA Operskalski. CD4 level as a diagnostic criterion for AIDS. Eighth International Conference on AIDS, Amsterdam, July 1992.

8. Transfusion Safety Study Group represented by JW Mosley. Idiopathic CD4+ lymphopenia: other lymphocyte changes, oral presentation. IXth International Conference on AIDS, Berlin, June 1993.
9. Transfusion Safety Study Group represented by EA Operskalski. Sex, age, and lymphocyte subsets associated with 3-year CD4+ stability in HIV infection. IXth International Conference on AIDS, Berlin, June 1993.
10. Transfusion Safety Study Group represented by MJ Nowicki. Anti-viral antibody levels in HIV-1 infected individuals. IXth International Conference on AIDS, Berlin, June 1993.

Partial Contributions

Published Papers

1. Perkins HA, Cordell R, Bueno C, Shiota J, Hitchcock B. The progressive decrease in the proportion of blood donors with antibody to human immunodeficiency virus (HIV). (Letter) *Transfusion* 1987;27:502.
2. Bishop PC, Boone DC, Parker JW. Immunophenotypes by flow cytometry: A longitudinal study in healthy individuals. *Diagnostic Clin Immunol* 1988;5:232-240.
3. Ulrich PP, Busch MP, El-Beik T, Shiota J, Vennari J, Shriver K, Vyas GN. Assessment of human immunodeficiency virus expression in cocultures of peripheral blood mononuclear cells from healthy seropositive subjects. *J Med Virol* 1988;25:1-10.
4. Busch MP, Young MJ, Samson SM, Mosley JW, Ward JW, Perkins HA, Transfusion Safety Study Group. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. *Transfusion* 1991;31:4-11.
5. Busch MP, Valinsky JE, Paglieroni T, Prince HE, GJ Crutcher, Gjerset GF, Operskalski EA, Charlebois E, Bianco C, Holland PV, Petersen LR, Hollingsworth CG, Mosley JW. Screening of blood donors for idiopathic CD4+ T-lymphocytopenia. *Transfusion* 1994;34:192-197.
6. Delwart EL, Busch MP, Kalish ML, Mosley JW, Mullins JI. Rapid molecular epidemiology of human immunodeficiency virus transmission. *AIDS Res Hum Retroviruses* 1995;11:1081-93.
7. Mosley JW, Huang W, Stram DO, Nowicki MJ, Hollinger FB, Aach RD, Stevens CE, Barbosa LH, Nemo GJ. Donor levels of serum alanine aminotransferase activity and antibody to hepatitis B core antigen associated with recipient hepatitis C and non-B, non-C outcomes. *Transfusion* 1996;36:776-81.
8. Kedes DH, Operskalski E, Busch M, Flood J, Kohn R, Ganem D. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. *Nature Medicine* 1996;2:1-7.
9. Diaz RS, Sabino EC, Mayer A, deOliveira CF, Mosley JW, Busch MP. Lack of dual HIV infection in a transfusion recipient exposed to two seropositive blood components. *AIDS Res Hum Retroviruses* 1996;12:1291-1295.

10. Diaz RS, Zhang L, Busch MP, Mosley JW, Mayer A. Divergence of HIV-1 quasispecies in an epidemiologic cluster. *AIDS* 1997;11:415-22.
11. Hilton JF, Donegan E, Katz MH, Canchola AJ, Fusaro RE, Greenspan D, Greenspan JS. Development of oral lesions in human immunodeficiency virus-infected transfusion recipients and hemophiliacs. *Am J Epidemiol* 1997;145:164-74.
12. Dille BJ, Surowy TK, Gutierrez RA, Coleman PF, Knigge MF, Carrick RJ, Aach RD, Hollinger FB, Stevens CE, Barbosa LH, Nemo GJ, Mosley JW, Dawson GJ, Mushahwar IK. ELISA for the detection of antibodies to the E2 protein of GBV-C. *J Infect Dis* 1997;175:458-61.
13. Zhang L, Diaz RS, Ho DD, Mosley JW, Busch MP, Mayer A. Host-specific driving force in human immunodeficiency virus type 1 evolution in vivo. *J Virol* 1997;71:2555-2561.
14. Mosley JW, Kim JP, Dawson GF, Aach RD, Hollinger FB, Stevens CD, Barbosa LH, Nemo GJ, Nowicki MJ. HGV/GBV-C detection among patients in the transfusion-transmitted viruses study. In: *Viral Hepatitis and Liver Disease. Proceedings of the IX Triennial International Symposium on Viral Hepatitis and Liver Disease (Rome)*. Turin: Edizioni Minerva Medica, 1997:368-371.

Accepted Conditionally

1. Wilkinson DA, Operskalski EA, Busch MP, Mosley JW, Koup RA. A 32 bp deletion within the CCR5 locus protects against transmission of parenterally-acquired human immunodeficiency virus but does not affect disease progression. *J Infect Disease*.

Published Abstracts

1. Diaz R, Sabino E, Mayer A, Mosley JW, Busch MP. Analysis of HIV-1 quasispecies in recipients of two seropositive transfusions: evidence of dual infection and viral recombination. *Transfusion* 1994;34(Suppl):46S.
2. Delwart E, Busch MP, Mosley JW, Mullins JI. Use of DNA heteroduplex tracking analysis of HIV quasispecies to establish linkage in cases of probable transfusion transmission. *Transfusion* 1994;34(Suppl):64S.

3. Diaz R, Sullivan M, Williams A, Lackritz E, Kessler D, Operskalski E, Mosley J, Busch M. Surveillance of HIV-1 subtypes in US blood donors: 1984 vs 1994. *Transfusion* 1995;35(Suppl):47S.
4. Mosley JW, Nowicki MJ, Hollinger FB, Aach RD, Stevens CE, Barbosa LH, Nemo GJ. Non-B non-C (NBNC) hepatitis rates and transfusion. *Blood* 1995;--:--
5. Mosley JW representing the Transfusion-transmitted Viruses Study Group. Recipient outcome and indirect donor screening. *Transfusion* 1995;35(Suppl):57S.
6. Diaz RS, Zhang ZQ, Busch MP, Mosley JW, Mayer A. Evolution of HIV-1 quaspecies in 3 patients infected from the same donor source. *Transfusion* 1995;35(Suppl):48S.
7. Busch MP, Rawal BD, Nowicki M, Operskalski EA, Mosley JW for the Retrovirus Epidemiology Donor Study and the Transfusion Transmitted Viruses Study. HCV RNA and ALT patterns in seroconverting transfusion recipients, and correlation with donor ALT and RNA. *Transfusion* 1997;37(Suppl):111S.
8. Laskus T, Wong LF, Rakela J, Nowicki MJ, Mosley JW. HCV donor exposures of previously HCV-uninfected and -infected recipients: Strain dynamics in the host. *Hepatology* 1997;--:--.

Presentations

1. Diaz R, Sabino E, Mayer A, Mosley JW, Busch MP. Evidence of HIV-1 recombination in a dually-exposed transfusion recipient. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, September 1994.
2. Diaz RS, Zhang LQ, Busch M, Mosley J, Mayer A. Concurrent evolution of HIV-1 in patients infected from the same source. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1995.
3. Diaz R, Sullivan M, Williams A, Lackritz E, Kessler D, Operskalski E, Mosley J, Busch M. Surveillance of HIV-1 subtypes in 222 US blood donors: Identification of first US subtype A infection. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1995.
4. Zhang LQ, Diaz RS, Mosley J, Busch M, Mayer A. Host-specific divergence of HIV-1 in patients infected from the same blood donor source. Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 1996.

5. Diaz RS, Zhang LQ, Mosley J, Busch M, Mayer A. Divergence of HIV-1 quasispecies in a sexual pair infected from the same blood donor source. Lack of continuous exchange of virus over time. Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 1996.
6. Diaz R, Sullivan M, Williams A, Lackritz E, Kessler D, Operskalski E, Mosley J, Busch M. Surveillance of HIV-1 subtypes in 222 US blood donors: Identification of first US subtype A infection. Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 1996.
7. Nowicki MJ, Kywe B, Yarbough PO. Hepatitis E virus antibody seroprevalence among blood donors from Myanmar and USA. IX Triennial International Symposium on Viral Hepatitis and Liver Disease, Rome, Italy, April 1996.
8. Nowicki MJ, Mosley JW, Aach RD, Hollinger FB, Stevens CE, Barbosa LH, Nemo GF. Hepatitis C virus transmission by blood from anti-HCV reactive donors. IX Triennial International Symposium on Viral Hepatitis and Liver Disease, Rome, Italy, April 1996.
9. Mosley JW, Kim JP, Dawson GF, Aach RD, Hollinger FB, Stevens CE, Barbosa LH, Nemo GF, Nowicki MJ. HGV/GBV-C cases among blood recipients and controls. IX Triennial International Symposium on Viral Hepatitis and Liver Disease, Rome, Italy, April 1996.
10. Diaz RS, de Oliveira CF, Sullivan M, Williams AE, Lackritz E, Kessler D, Operskalski EA, Mosley JW, Busch MP. Surveillance of HIV-1 genetic variation in US blood donors using heteroduplex mobility assay. 38th Annual Meeting of the American Society of Hemophilia, Orlando, FL, December 6-10, 1996.
11. Diaz RS, de Oliveira CF, Mosley JW, Busch MP. Use of the tat gene of HIV-1 to establish epidemiological relationships among HIV-1 infected couples. XI International Conference on AIDS, Vancouver, Canada, July 1996.
12. Diaz RS, deOliveira CF, Mayer A, Zanotto P, Sabino E, Mosley JW, Busch MP. Evidence of enhanced region diversity and recombination in a dually infected transfusion recipient. 4th Conference on Retroviruses and Opportunistic Infections, Washington DC, January 1997.